P3.17-22 Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Autor:	Bo Lu, Grace L. Lu-Yao, R. Axelrod, Dawn Poller, Maria Werner-Wasik, Ralph Zinner, D.C. Hooper, Scott W. Cowan, B. Leiby, C. Solomides, Hushan Yang, Jennifer Johnson, L. Harshyne, Athanassios Argiris, Nathaniel R. Evans, L. Phan
Rok vydání:	2018
Předmět:	Pulmonary and Respiratory Medicine Cisplatin Pemetrexed Oncology business.industry medicine Cancer research Cisplatin/gemcitabine Nivolumab business medicine.drug
Zdroj:	Journal of Thoracic Oncology. 13:S1028-S1029
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2018.08.1978
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::eb18fbcf8e94fddd409f9bf237df2421 https://doi.org/10.1016/j.jtho.2018.08.1978 Zobrazit plný text záznamu